Biophytis SA and LynxKite Technologies announced a significant expansion of their partnership on March 13, 2026, aimed at advancing AI-driven drug discovery for next-generation longevity therapies. This collaboration will enhance the existing MASSIVE project, which focuses on developing novel drug candidates targeting sarcopenia, a degenerative muscle disease prevalent among the elderly.
The partnership is set to generate revenue through a newly established computational longevity platform. This platform will feature unique curated datasets and innovative computation methods tailored for longevity research. It will also facilitate the development of drug candidates targeting both sarcopenia and dry age-related macular degeneration, conditions that significantly impact older populations worldwide.
Details of the Collaboration
This strategic initiative, supported by Enterprise Singapore, aligns with the key objectives outlined in Singapore’s Research, Innovation and Enterprise (RIE) 2030 plan. LynxKite, known for its expertise in advanced analytics and artificial intelligence, will incorporate AI computational methods into its platform to bolster longevity research efforts. The company has a proven track record, having assisted over 100 global enterprises, including major firms like Roche and AstraZeneca, in navigating complex data through advanced AI approaches.
The MASSIVE project is designed to identify and develop activators of the Mas receptor (MasR), which plays a critical role in combating sarcopenia. The first phase aims to leverage Biophytis’ extensive experience in age-related diseases and MasR pharmacology. The collaboration will also utilize LynxKite’s cutting-edge AI technologies and chemoinformatics to enhance drug discovery efficiency.
Key objectives of the project include:
– Modeling the Mas receptor for structure-based drug design using AI tools.
– Designing and prioritizing synthetic drug candidates through AI-guided molecule generation.
– Synthesizing and testing promising MasR activators to evaluate their biological activity and safety.
– Preparing for preclinical development by filing patents for lead candidates.
– Validating AI software through continuous feedback from laboratory tests.
Statements from Leadership
“The launch of MASSIVE marks a decisive step in our longevity strategy, combining our clinical expertise with LynxKite’s innovative AI to accelerate the discovery of transformative therapies against sarcopenia,” said Stanislas Veillet, CEO of Biophytis.
In response, Gyorgy Lajtai, CEO of LynxKite, expressed pride in collaborating with Biophytis, emphasizing the potential of their platform to revolutionize drug discovery by integrating relevant computational tools across various modalities.
About the Companies
Biophytis SA is a clinical-stage biotechnology company dedicated to developing drug candidates for age-related diseases. Its lead candidate, BIO101 (20-hydroxyecdysone), is currently in advanced developmental stages for treating muscular diseases and metabolic disorders. Biophytis is headquartered in Paris, France, with additional offices in Cambridge, Massachusetts, and Brazil.
LynxKite Technologies, based in Singapore, specializes in advanced analytics and AI solutions. The company’s platform integrates graph analytics and biological language models, optimizing GPU resources to efficiently execute complex analytical pipelines.
As both companies continue to innovate, the partnership is expected to play a pivotal role in enhancing the landscape of longevity therapeutics, ultimately improving the quality of life for aging populations globally.
